These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32875998)

  • 21. Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism.
    Grabner M; Hepp Z; Raval A; Tian F; Khera M
    J Sex Med; 2018 Feb; 15(2):148-158. PubMed ID: 29425664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testosterone supplementation does not worsen lower urinary tract symptoms.
    Pearl JA; Berhanu D; François N; Masson P; Zargaroff S; Cashy J; McVary KT
    J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review.
    Shabsigh R; Crawford ED; Nehra A; Slawin KM
    Int J Impot Res; 2009; 21(1):9-23. PubMed ID: 18633357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The state of testosterone therapy since the FDA's 2015 labelling changes: Indications and cardiovascular risk.
    Miner M; Morgentaler A; Khera M; Traish AM
    Clin Endocrinol (Oxf); 2018 Jul; 89(1):3-10. PubMed ID: 29486065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Varicocele Repair Versus Testosterone Therapy for Older Hypogonadal Men with Clinical Varicocele and Low Testosterone.
    Bernie HL; Goldstein M
    Eur Urol Focus; 2018 Apr; 4(3):314-316. PubMed ID: 30316825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testosterone therapy improves erectile function and libido in hypogonadal men.
    Rizk PJ; Kohn TP; Pastuszak AW; Khera M
    Curr Opin Urol; 2017 Nov; 27(6):511-515. PubMed ID: 28816715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythrocytosis Following Testosterone Therapy.
    Ohlander SJ; Varghese B; Pastuszak AW
    Sex Med Rev; 2018 Jan; 6(1):77-85. PubMed ID: 28526632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome.
    Hackett G
    Sex Med Rev; 2019 Jul; 7(3):476-490. PubMed ID: 30803918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Testosterone treatment and cardiovascular and venous thromboembolism risk: what is 'new'?
    Corona G; Dicuio M; Rastrelli G; Maseroli E; Lotti F; Sforza A; Maggi M
    J Investig Med; 2017 Aug; 65(6):964-973. PubMed ID: 28495861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morbidity and mortality in men: Role of androgens.
    Fallara G; Pozzi E; Corsini C; Belladelli F; Boeri L; Capogrosso P; Montorsi F; Salonia A
    Best Pract Res Clin Endocrinol Metab; 2022 Jul; 36(4):101662. PubMed ID: 35484028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice.
    Rhoden EL; Morgentaler A
    J Sex Med; 2010 Jan; 7(1 Pt 1):277-83. PubMed ID: 20104673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Testosterone replacement therapy and cardiovascular risk].
    Corona G; Dicuio M; Rastrelli G; Sforza A; Maggi M
    G Ital Cardiol (Rome); 2017 Nov; 18(11):745-753. PubMed ID: 29105668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry.
    Morales A
    BJU Int; 2011 May; 107(9):1369-73. PubMed ID: 21518230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Testosterone therapy: Prescribing and monitoring patterns of practice in British Columbia.
    Locke JA; Flannigan R; Günther OP; Skeldon S; Goldenberg SL
    Can Urol Assoc J; 2021 Feb; 15(2):E110-E117. PubMed ID: 32745001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What are the benefits and harms of testosterone therapy for male sexual dysfunction?-a systematic review.
    Dimitropoulos K; Verze P; Van den Broeck T; Salonia A; Yuan CY; Hatzimouratidis K; Dohle G
    Int J Impot Res; 2019 Nov; 31(6):380-391. PubMed ID: 30918363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
    Rhoden EL; Morgentaler A
    J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obstructive Sleep Apnea and Testosterone Therapy.
    Payne K; Lipshultz LI; Hotaling JM; Pastuszak AW
    Sex Med Rev; 2021 Apr; 9(2):296-303. PubMed ID: 32636155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
    Traish AM
    Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testosterone and the prostate: implications for the treatment of hypogonadal men.
    Holyoak JD; Crawford ED; Meacham RB
    Curr Urol Rep; 2008 Nov; 9(6):500-5. PubMed ID: 18947516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.